Verapamil and Photodynamic Therapy for Tumor Destruction
Author Information
Author(s): L. Gossner, H. Wittkel, A. Warzechal, R. Sroka, H. Ernst, M. Meier, C. Ell
Primary Institution: University of Erlangen - Nuremberg
Hypothesis
Does verapamil enhance the effectiveness of photodynamic therapy in tumor destruction?
Conclusion
Verapamil does not enhance photodynamic destruction of tumors when administered with low doses of hematoporphyrin derivative.
Supporting Evidence
- Verapamil did not enhance the regrowth delay time in fibrosarcoma.
- Both regrowth delay and extent of tissue necrosis were similar in treated and untreated groups.
- Verapamil alone did not affect tumor growth or necrosis.
Takeaway
The study tested if a heart medicine called verapamil could help a light treatment for tumors work better, but it didn't make a difference.
Methodology
Two tumor models were used: fibrosarcoma SSK-2 in mice and human adenocarcinoma of the colon in nude mice, with treatments administered and effects measured.
Limitations
The study used low doses of the photosensitizer, which may not be applicable to clinical settings.
Participant Demographics
Female inbred C3H-mice and nude mice were used in the experiments.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website